Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10970387 | Vaccine | 2008 | 7 Pages |
Abstract
In clinical trials recombinant-modified vaccinia virus Ankara expressing the Mycobacterium tuberculosis antigen 85A (MVA85A) induces approximately 10 times more effector T cells than any other recombinant MVA vaccine. We have found that in BCG primed subjects MVA85A vaccination reduces transforming growth factor beta 1 (TGF-β1) mRNA in peripheral blood lymphocytes and reduces TGF-β1 protein in the serum, but increases IFN-γ ELISPOT responses to the recall antigen SK/SD. TGF-β1 is essential for the generation of regulatory T cells and we see a correlation across vaccinees between CD4+CD25hiFoxP3+ cells and TGF-β1 serum levels. This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Helen A. Fletcher, Ansar A. Pathan, Tamara K. Berthoud, Susanna J. Dunachie, Kathryn T. Whelan, Nicola C. Alder, Clare R. Sander, Adrian V.S. Hill, Helen McShane,